国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2011年
21期
1633-1635
,共3页
王伟华%郑逸华%周爱新%林雪梅%毛娟华%李振华
王偉華%鄭逸華%週愛新%林雪梅%毛娟華%李振華
왕위화%정일화%주애신%림설매%모연화%리진화
莫西沙星%左氧氟沙星%恶性肿瘤%社区获得性肺炎
莫西沙星%左氧氟沙星%噁性腫瘤%社區穫得性肺炎
막서사성%좌양불사성%악성종류%사구획득성폐염
Moxifloxacin%Levofloxacin%Malignant tumor%Community-acquired pneumonia
目的 研究莫西沙星治疗恶性肿瘤合并社区获得性肺炎(CAP)的疗效和安全性.方法 118例恶性肿瘤合并CAP病例随机分为治疗组(60例)和对照组(58例).治疗组应用莫西沙星治疗,对照组应用左氧氟沙星治疗,观察其疗效和安全性.结果 两组总有效率分别是88.3%和62.1%,痊愈率分别是48.3%和34.5%,两组共分离细菌65株,细菌清除率分别为87.9%和62.5%(P<0.05),不良反应发生率分别为5.0%和10.3%(P<0.05).结论 莫西沙星治疗恶性肿瘤合并CAP患者临床疗效好,细菌清除率高,使用安全.
目的 研究莫西沙星治療噁性腫瘤閤併社區穫得性肺炎(CAP)的療效和安全性.方法 118例噁性腫瘤閤併CAP病例隨機分為治療組(60例)和對照組(58例).治療組應用莫西沙星治療,對照組應用左氧氟沙星治療,觀察其療效和安全性.結果 兩組總有效率分彆是88.3%和62.1%,痊愈率分彆是48.3%和34.5%,兩組共分離細菌65株,細菌清除率分彆為87.9%和62.5%(P<0.05),不良反應髮生率分彆為5.0%和10.3%(P<0.05).結論 莫西沙星治療噁性腫瘤閤併CAP患者臨床療效好,細菌清除率高,使用安全.
목적 연구막서사성치료악성종류합병사구획득성폐염(CAP)적료효화안전성.방법 118례악성종류합병CAP병례수궤분위치료조(60례)화대조조(58례).치료조응용막서사성치료,대조조응용좌양불사성치료,관찰기료효화안전성.결과 량조총유효솔분별시88.3%화62.1%,전유솔분별시48.3%화34.5%,량조공분리세균65주,세균청제솔분별위87.9%화62.5%(P<0.05),불량반응발생솔분별위5.0%화10.3%(P<0.05).결론 막서사성치료악성종류합병CAP환자림상료효호,세균청제솔고,사용안전.
Objective To research the curative effect and security of moxifloxacin on malignant tumor with community-acquired pneumonia.Methods 118 patients with malignant tumor combined with community-acquired pneumonia were randomly divided into treatment group (60 cases) and control group (58 cases).The treatment group and control group were treated with moxifloxacin and levofloxacin,respectively.Then the curative effect and security were observed.Results The total effective rates were 88.3% and 62.1%,cure rates were 48.3% and 34.5% in treatment group and control group,respectively.Totally,the two groups isolated 65 bacterium.The bacterial clearance rates were 87.9% and 62.5%,and the incidence of adverse events were 5.0% and 10.3% in treatment group and control group,respectively ( P <0.05).Conclusions This study suggests that moxifloxacin is an effective and safe drug with high bacterial clearance rate for treating cancer patients with community-acquired pneumonia.